Brief: Palatin Announces Initiation of Pivotal Phase 3 PL9643 MELODY-1 Clinical Trial in Patients with Dry Eye Disease
28/12/2021 12:33
Dec 28 (Reuters) - Palatin Technologies Inc PTN.A :
* PALATIN ANNOUNCES INITIATION OF PIVOTAL PHASE 3 PL9643
MELODY-1
CLINICAL TRIAL IN PATIENTS WITH DRY EYE DISEASE
* PALATIN TECHNOLOGIES INC - TOP-LINE RESULTS CURRENTLY
EXPECTED
SECOND HALF CALENDAR 2022
Source text for Eikon: ID:nPn9jKDqda
Further company coverage: PTN.A
((Reuters.Briefs@thomsonreuters.com;;))
Recent news on Palatin Technologies
See all newsPalatin Technologies Inc reports results for the quarter ended March 31 - Earnings Summary
Palatin Technologies Inc expected to post a loss of $1.20 a share - Earnings Preview
Palatin Technologies Q2 revenue rises yr/yr, net loss widens
Brief: Palatin Announces 1-For-50 Reverse Stock Split
Brief: Palatin Announces Positive Preclinical Efficacy Data For Oral MC4R Agonist PL7737 In Animal Model Of Obesity